Universidad Peruana Cayetano Heredia

Reply to Garg et al, Smith et al, and Persichino and Miller.

Mostrar el registro sencillo del ítem

dc.contributor.author White, A. Clinton Jr
dc.contributor.author Coyle, Christina M.
dc.contributor.author Rajshekhar, Vedantam
dc.contributor.author Singh, Gagandeep
dc.contributor.author Hauser, W. Allen
dc.contributor.author Mohanty, Aaron
dc.contributor.author García Lescano, Héctor Hugo
dc.contributor.author Nash, Theodore E.
dc.date.accessioned 2019-03-05T15:25:02Z
dc.date.available 2019-03-05T15:25:02Z
dc.date.issued 2018
dc.identifier.uri https://hdl.handle.net/20.500.12866/5926
dc.description.abstract We thank Garg and colleagues for their letter. Two randomized trials compared albendazole and combination therapy with simultaneous praziquantel and albendazole. In both cases, the radiologic response was better with combination therapy only in patients with >2 viable parenchymal cysts but not in those with ≤2 cysts. These trials were the basis for the distinction in treatment of viable parenchymal disease distinguishing patients with 1 or 2 parenchymal cysts form those with ≥3 parenchymal cysts or viable parenchymal cysticercosis. However, neither of these trials included patients with >20 cysticerci. en_US
dc.language.iso eng
dc.publisher Oxford University Press
dc.relation.ispartofseries Clinical Infectious Diseases
dc.rights info:eu-repo/semantics/restrictedAccess
dc.rights.uri https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.subject Correspondence en_US
dc.title Reply to Garg et al, Smith et al, and Persichino and Miller. en_US
dc.type info:eu-repo/semantics/article
dc.identifier.doi https://doi.org/10.1093/cid/ciy437
dc.subject.ocde https://purl.org/pe-repo/ocde/ford#3.03.08
dc.relation.issn 1537-6591


Ficheros en el ítem

Ficheros Tamaño Formato Ver

No hay ficheros asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

info:eu-repo/semantics/restrictedAccess Excepto si se señala otra cosa, la licencia del ítem se describe como info:eu-repo/semantics/restrictedAccess

Buscar en el Repositorio


Listar

Panel de Control

Estadísticas